Abstract:Introduction: Vascular Endothelial Growth Factor (VEGF) is associated with abnormal fundus neovascularization. Consequently, Anti-VEGF agents are vital for ophthalmic treatment. This paper reviews the application of anti-VEGF agents in ophthalmology over the past two decades with the aim of providing insights for further research. Methods: A meticulous search strategy was employed in the Web of Science Core Collection literature from 2003 to 2023 to gather relevant literature, which was then analyzed using VOSviewer, CiteSpace, and the R package Bibliometrix. Results: The study included 3,602 publications from 83 countries and 3,445 institutions. The United States and China have emerged as leading contributors in terms of the publication volume. Johns Hopkins University, the University of Sydney, and Genentech Inc were identified as frontrunners in this field. "Retina" had the highest publication volume, whereas "Ophthalmology" had the highest citation frequency. Among the 15,918 scholars, Bressler NM, Holz FG, Glassman AR, and Bandello F led in publication volume, while Brown DM was the most cited author. High-frequency keywords included "Endothelial Growth Factor," "Therapy," "Safety," and "Randomized Clinical Trial." Conclusion: Anti-VEGF drugs have shown notable success in treating neovascular eye diseases, especially wet age-related macular degeneration and diabetic macular edema, focusing on clinical efficacy, injection regimens, and safety. Future directions include developing new anti-VEGF drugs, drug delivery systems, non-invasive administration, multi-target drugs, leveraging big data and artificial intelligence, and addressing the current treatment limits. Continuous innovation and method improvement in this field promise more breakthroughs, providing effective, safe, and economical options for eye disease treatment.

Progression and Challenge of Anti-Vascular Endothelial Growth Factor Therapy in Retinal Neovascular Disease

Progress of Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease: Benefits and Challenges

Progression and challenge of therapeutic strategies in neovascular age-related macular degeneration

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

Anti-VEGF therapy in pediatric retinal and choroidal disease

Clinical Research Progress of Anti-Vegf Agents for Diabetic Retinopathy

Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis

[The Rational Use of Anti-Vascular Endothelial Growth Factor Drugs to Assist the Treatment of Diabetic Retinopathy].

Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization

The Application of anti-vascular endothelial growth factor therapy in ophthalmology

Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases

Vascular Endothelial Growth Factor and Diabetic Retinal Disease

Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation

Exploring neovascular age-related macular degeneration and diabetic macular edema and advances in treatment

[Intraocular Antiangiogenic Drugs in Clinical Application Advantages and Disadvantages].

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

Recent advances in the treatment and delivery system of diabetic retinopathy

Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?